Clinical Trial Update: A Phase 1 Study of ADI-001 in B Cell Malignancies [Phase 1]

View source ↗

Summary

The Phase 1 study of ADI-001 in B cell malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ADI-001

Snippet

Sponsor: Adicet Therapeutics | Conditions: Lymphoma, Follicular, Lymphoma, Mantle-Cell | Phase 1 | Status: TERMINATED